Antipsychotic Drugs: Oversold and Under-Warned

Antipsychotic drugs have now become the top-selling class of prescription drugs in the United States, with $14.6 billion in annual revenue. Quite a trick for a group of drugs approved for one percent or less of the population.

But now you can go into any nursing home or elementary school and find non-psychotic patients taking these anti-psychotic drugs every day. Therein lies a marketing story for pharmaceutical manufacturers, who have danced around FDA regulations intended to keep the drugs marketed for only proven and safe uses.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Patrick Malone & Associates P.C. | DC Injury Lawyers | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

CONNECT

About Patrick Malone: Patrick Malone is a leading patient safety advocate and attorney who... View Profile »


Follow Patrick Malone & Associates P.C. | DC Injury Lawyers:

Reporters on Deadline

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.
×
Loading...
×
×